Cytiva debuted a new cell therapy manufacturing platform it developed in collaboration with Gilead Sciences’ Kite Pharma unit. (Cytiva) Cytiva, a biopharma research and manufacturing specialist, ...

Biopharma’s ongoing quest to develop COVID-19 drugs and vaccines, plus growing industry demand for producing various types of new therapies, are fueling the $1.5-billion expansion of manufacturing ...

Cambridge, UK and Marlborough, MA, 28 May 2025: Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a ...

Quick ReadDanaher (DHR) locks biopharma customers into Cytiva's workflows through astronomical switching costs, turning over ...

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and ...

Now offering Cytiva Diagnostic Services, new diagnostic test development and support service virtually or at new lab, for point-of-care diagnostic developers to increase speed to market of new tests.

Lehi, June 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah – June 3rd, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system ...

Cytiva needed to expand its clean room capabilities to install additional and updated liquid pharmaceutical formulation and bottling equipment, which involved a new stand-alone structure on the Cytiva ...

Cytiva, the former BioPharma business of GE Healthcare Life Sciences now owned by Danaher, said it will invest $500 million and hire 1,000 people over the next five years in an expansion of its global ...

Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular ...

Now offering Cytiva Diagnostic Services, new diagnostic test development and support service virtually or at new lab, for point-of-care diagnostic developers to increase speed to market of new tests.